OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the
risk for coronary heart disease death (CHD death), myocardial infarction, or urgent
coronary revascularization in participants at risk for a first major cardiovascular event
wit...
Age: 50 - 105 years
Gender: All
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
This prospective, multicenter, cluster-randomized controlled study aims to evaluate the
accuracy of an investigational artificial intelligence (AI) Software as a Medical Device
(SaMD) designed to compute ejection fraction (EF) severity categories based on the
America...
Age: 18 years - 66+
Gender: All
SELUTION 4 De Novo Small Vessel IDE Trial
Prospective, randomized controlled, single-blind, multicenter, clinical trial to
demonstrate the safety and efficacy of the SELUTION SLR 014 PTCA DEB for treatment of de
novo lesions in small coronary vessels, defined as reference vessel diameter (RVD) of
2.00 mm to ...
Age: 18 years - 66+
Gender: All